Pediatric Dermatology最新文献_第6页

Juvenile Hyaline Fibromatosis Syndrome: A Novel Variant in the ANTXR2 Gene Causing Severe Phenotype. 少年透明纤维瘤病综合征：ANTXR2基因的新变异导致严重表型。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-04 DOI: 10.1111/pde.70027

Ilayda Akyon, Ozgenur Ozen, Mustafa Dogan, Zafer Turkoglu, Dilay Bastug, Fatmagul Kusku Cabuk, Alper Gezdirici

引用次数: 0

Prevalence, Age of Onset, Age at Diagnosis, and Family History of Hidradenitis Suppurativa in Pediatric Populations: A Systematic Review and Meta-Analysis. 儿童人群中化脓性汗腺炎的患病率、发病年龄、诊断年龄和家族史：系统回顾和荟萃分析。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-04 DOI: 10.1111/pde.70022

Grace Xiong, Mohamed Ali, Erfan Ghani Kakhki, Annie Xiong, Raed Alhusayen, David Croitoru, Cathryn Sibbald, Vincent Piguet, Ilya Mukovozov

{"title":"Prevalence, Age of Onset, Age at Diagnosis, and Family History of Hidradenitis Suppurativa in Pediatric Populations: A Systematic Review and Meta-Analysis.","authors":"Grace Xiong, Mohamed Ali, Erfan Ghani Kakhki, Annie Xiong, Raed Alhusayen, David Croitoru, Cathryn Sibbald, Vincent Piguet, Ilya Mukovozov","doi":"10.1111/pde.70022","DOIUrl":"https://doi.org/10.1111/pde.70022","url":null,"abstract":"Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses in intertriginous areas, ultimately resulting in scarring and formation of sinus tracts. HS significantly impacts quality of life and can also affect pediatric populations. We aimed to determine the prevalence, family history, age of onset, and age at diagnosis of HS in pediatric populations.Methods: A random-effects meta-analysis of observational studies was conducted following MOOSE guidelines. Five databases were searched through May 2024.Results: Thirty seven observational studies were included, representing 6941 patients from 13 countries. The weighted mean age was 14.7 years (range: 4-18). Ethnoracial distribution included White (36.5%), Black (38.3%), Hispanic (13.9%), Asian (0.8%), Indigenous (0.2%), Middle Eastern (0.7%), multiracial (1.2%), and unspecified populations (8.4%). Among studies reporting severity, 42.5% had Hurley Stage I, 46.3% Stage II, and 11.2% Stage III. The prevalence of HS in pediatric populations was 0.03% (95% CI [0.0001, 0.0005]), with 38% of patients having a family history of HS (95% CI [0.30, 0.45]). Pediatric-onset HS predominantly affects females (78%, 95% CI [0.76, 0.80]). The average age of onset of HS in pediatric populations was 11.3 years (95% CI [10.15, 12.39]), but diagnosis typically occurred at 14.0 years (95% CI [12.65, 15.28]), indicating a delay in diagnosis. Female predominance of HS was associated with earlier age of onset and age at diagnosis, while no significant correlations between family history, age of onset, or age at diagnosis were identified.Conclusion: This study highlights the characteristics of pediatric-onset HS and emphasizes the need for earlier detection to expedite diagnosis and initiation of treatment.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention of Atopic Dermatitis in High-Risk Infants: A Review of the Role of Lipid-Based Barrier Repair Therapy. 高危婴儿特应性皮炎的预防：脂质屏障修复疗法的作用综述。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-04 DOI: 10.1111/pde.70010

Chon-Wai Jeremy Chan, Marty O Visscher

{"title":"Prevention of Atopic Dermatitis in High-Risk Infants: A Review of the Role of Lipid-Based Barrier Repair Therapy.","authors":"Chon-Wai Jeremy Chan, Marty O Visscher","doi":"10.1111/pde.70010","DOIUrl":"https://doi.org/10.1111/pde.70010","url":null,"abstract":"Background/objective: Growing evidence highlights the role of physiological lipids, namely ceramides, cholesterol, and free fatty acids, in maintaining skin barrier function and preventing atopic dermatitis (AD). Current evidence on the efficacy, safety, and clinical relevance of stratum corneum (SC) lipid-based therapies to prevent AD and increase skin barrier integrity in high-risk infants was reviewed and synthesized.Methods: Searches with key words lipid-based therapy, atopic dermatitis, infant, and prevention were conducted to identify papers using PubMed, Embase, Cochrane Library, and Scopus databases from January 2000 to June 2024.Results: SC lipid-based therapies were reported to replenish deficient SC lipids, thereby improving skin barrier function, a critical aspect of AD management. These therapies reduced SCORAD scores, enhanced hydration, and improved epidermal cohesion, with some studies reporting comparable efficacy to topical corticosteroids when used as adjunct treatments. However, evidence supporting their effectiveness in preventing AD onset in infants remains limited, with only trends toward reduced AD incidence and food sensitization reported, without statistical significance. Importantly, SC lipid therapies are well tolerated, with no significant adverse effects noted, supporting their safety in infants and children.Conclusion: This review ascertained knowledge gaps that can direct research and resolve controversies regarding emollients. Mechanistic studies in high-risk and non-atopic infants, starting at birth, are warranted using within-subject comparisons and frequent evaluations, including SC sampling for proteomics and lipidomics outcomes for mechanistic insight. Studies should begin with relatively simple formulations, for example, containing only ceramides, cholesterol, and fatty acids matched to varying infant SC lipid profiles at birth and over time.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe Oral Lichen Planus Masking a Primary Immunodeficiency: X-Linked Lymphoproliferative Disease Type 1 (XLP-1). 掩盖原发性免疫缺陷的严重口腔扁平苔藓：x连锁淋巴增生性疾病1型（XLP-1）。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-04 DOI: 10.1111/pde.70025

Magí Brufau-Cochs, Ángela Deya Martínez, Mariana Álvarez Vukov, Laura Martí-Sánchez, Claudia Fortuny Guasch, Eulàlia Baselga Torres

引用次数: 0

A Case Report of a Mild and Atypical Presentation of Proteus Syndrome. 轻度非典型变形肌综合征1例报告。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-03 DOI: 10.1111/pde.70035

Camilo E Alarcón-Pérez, Marta Ivars, Cinzia Lavarino, Sonia Paco, Antonio Martínez-Monseny, Eulàlia Baselga-Torres

引用次数: 0

Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. 评价儿童患者使用杜匹单抗治疗特应性皮炎的减毒活疫苗的效果。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-02 DOI: 10.1111/pde.70033

Grace Eleanor Sessler Bruess, Kelly K Barry, Gerilyn M Olsen, Cristina M Foschi, Elizabeth Cook, Melodee Liegl, Amy Y Pan, Leah Lalor

引用次数: 0

Cutaneous Rosai-Dorfman Disease Mimicking Granulomatous Dermatoses: A Rare Case Report. 皮肤Rosai-Dorfman病模拟肉芽肿性皮肤病：罕见病例报告。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-02 DOI: 10.1111/pde.70017

Vinolyn Dsouza, Jyothi Jayaraman, Eswari Loganathan, Preethi Rai Ariadka, Chandana Pai, Jacintha Martis, Rochelle Cheryl Monteiro, Prajna Shetty

引用次数: 0

A Case of Lipschütz Ulcers in a 13-Year-Old Girl With PFAPA Syndrome. 13岁女孩PFAPA综合征并发lipschschtz溃疡1例。

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-01 Epub Date: 2025-04-02 DOI: 10.1111/pde.15926

Remi Parker, Hannah Russell Johns, Crystal Pourciau

引用次数: 0

Trends in Healthcare Utilization and Treatments of Infantile Hemangioma in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) 2009-2019. 美国婴儿血管瘤的医疗保健利用和治疗趋势：2009-2019年国家门诊医疗调查（NAMCS）分析

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-01 Epub Date: 2025-08-28 DOI: 10.1111/pde.16040

Mohsen Afarideh, Katelyn R Anderson, Megha M Tollefson

{"title":"Trends in Healthcare Utilization and Treatments of Infantile Hemangioma in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) 2009-2019.","authors":"Mohsen Afarideh, Katelyn R Anderson, Megha M Tollefson","doi":"10.1111/pde.16040","DOIUrl":"10.1111/pde.16040","url":null,"abstract":"Background: Recent data demonstrate increased incidence of Infantile hemangioma (IH) over the past several decades. However, little is known about current trends in healthcare utilization and medication prescribing in patients with IH in the United States (US), particularly since the discovery and uptake of beta-blockers as standard of care treatment.Methods: We examined US ambulatory visits in infants (age ≤ 1 years) with any hemangioma (International Classification of Diseases [ICD] 9th Revision codes 228.00, 228.01, or 228.09 in the National Ambulatory Medical Care Survey [NAMCS] 2009-2015, and ICD 10th Revision code D18.0 in the NAMCS 2016-2019). We further trended the prescription of topical and systemic IH treatments during this period.Results: Years of visit were bundled into 5-year bins to minimize standard errors for the trend tests. The number of visits related to IH significantly increased from 878,725 (95% CI: 439,376-1,318,074) in 2009-2013 to 1,431,913 (95% CI: 940,036-1,923,790, p = 0.022) in 2014-2019. The number of visits with resulting timolol prescription concurrently significantly increased from 16,279 (95% CI: 0-40,600) to 424,845 (95% CI: 380,786-468,903, p < 0.001), while the increase in the number of propranolol prescriptions was nonsignificant (from 162,323 [95% CI: 0-331,537] to 208,139 [95% CI: 0-558,709], p = 0.652).Conclusions: The US healthcare utilization for IH has been on the rise between 2009 and 2019, likely owing to increased awareness, earlier diagnosis, and enhanced therapies. While topical beta-blocker prescriptions have significantly increased during that period of time, systemic beta-blocker prescription rates have not.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":"946-955"},"PeriodicalIF":1.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What are topical steroids? 什么是局部类固醇？

IF 1.2 4区医学

Pediatric Dermatology Pub Date : 2025-09-01 DOI: 10.1111/pde.70020

引用次数: 0